Science & Enterprise subscription

Follow us on Twitter

  • A company designing gene-edited T-cells as cancer therapies stopped its clinical trial of a treatment for multiple… https://t.co/0PktfkzyNH
    about 2 hours ago
  • New post on Science and Enterprise: FDA Halts Off-the-Shelf Engineered T-Cell Trial https://t.co/Fbz7IKCgky #Science #Business
    about 2 hours ago
  • If you dig deep into the Science & Enterprise archives, you'll find this site began posting on 6 July 2010, exactly… https://t.co/eGPudMExsK
    about 18 hours ago
  • New post on Science and Enterprise: Essay – Ten Years and Counting https://t.co/bIFz5ld4g4 #Science #Business
    about 18 hours ago
  • A cocktail of two synthetic antibodies will soon be tested in a clinical trial to prevent against Covid-19 infectio… https://t.co/auyvJKhyBq
    about 21 hours ago

Please share Science & Enterprise

Non-Invasive Fetal Oxygen Monitor Designed

TFO device

A university engineering lab created a device that safely monitors a fetus’s blood oxygen levels from outside the mother’s abdomen, which could reduce the rate of cesarean sections. . . . → Read More: Non-Invasive Fetal Oxygen Monitor Designed

Cancer Drug Technology Licensed for Covid-19

Paula Bates

A biotechnology company is licensing medical research discoveries from university labs first designed for treating cancer as a potential Covid-19 therapy. . . . → Read More: Cancer Drug Technology Licensed for Covid-19

Industry, Univ. Labs Partner on Covid-19 Therapy

Covid-19 illustration

Researchers from industry and academic labs are developing a synthetic antibody that in lab tests shows promise as both a Covid-19 therapy and vaccine. . . . → Read More: Industry, Univ. Labs Partner on Covid-19 Therapy

Start-Up Creating a Simpler, Stable Liquid Biopsy

Blood vials

A new company spun off from University of Oxford is developing a stable and sensitive blood test to detect multiple types of cancer in their early stages. . . . → Read More: Start-Up Creating a Simpler, Stable Liquid Biopsy

Biotechs Apply Crispr Gene-Editing for Hemophilia

Crispr-Cas9 illustration

A treatment for the blood disease hemophilia and other inherited disorders are being developed with the gene-editing technology Crispr in a biotechnology deal. . . . → Read More: Biotechs Apply Crispr Gene-Editing for Hemophilia

Drug Maker Licenses Low-Dose Vaccine Patch

Nanopatch system

The pharmaceutical company Merck is licensing a microneedle patch device that delivers vaccines with a small fraction of the dose normally needed by syringes. . . . → Read More: Drug Maker Licenses Low-Dose Vaccine Patch

Health Research Commercialization Company Launched

Microscope

University of Michigan and health care investor Deerfield Management are creating a new enterprise to bring promising academic life science research to market. . . . → Read More: Health Research Commercialization Company Launched

Merck Inks Three Covid-19 Vaccine, Therapy Deals

SARS-Cov-2 virus

Drug maker Merck today gained a new acquisition, along with collaboration and licensing deals, for vaccines and a therapy for Covid-19 infections. . . . → Read More: Merck Inks Three Covid-19 Vaccine, Therapy Deals

Depression Therapy Licensed for Online Distribution

Man with depression

A therapy program for depression designed to reduce spirals of repeated negative thinking is licensed to a digital mental health company for online use. . . . → Read More: Depression Therapy Licensed for Online Distribution

Pharmas License A.I.-Aided Gene Therapies

Retinal gene therapy

A university spin-off company designing synthetic viruses with artificial intelligence to deliver gene therapies is licensing its work for eye and muscle disorders. . . . → Read More: Pharmas License A.I.-Aided Gene Therapies